Abstract
BackgroundHigh dose immunossuppression (HDI) followed by autologous hematopoietic stem cell transplantation (AHSCT) emerged in last past years as a therapeutic alternative for systemic sclerosis (SSc) patients [1]. The evaluation of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
